This article is more than 5 years old. Information may no longer be current.

FDA approves third-generation nebulizer for inhalation system

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA approved a new inhalation device for use with a treprostinil inhalation system for the treatment of pulmonary arterial hypertension, according to a press release from United Therapeutics.

Treprostinil (Tyvaso) was approved in 2009 and the inhalation system consists of the drug product, an ultrasonic nebulizer and accessories. The Tyvaso system is the most prescribed inhalation therapy for PAH in the U.S., according to the release.

The new nebulizer, TD-300/A, is more ergonomic with a single button operation, an intuitive user face and an internal, rechargeable battery, the company stated in the release.

“Tyvaso is an important element of our continuum of care, which provides a range of treprostinil therapy options across a spectrum of PAH patients,” Michael Benkowitz, president and chief operating officer of United Therapeutics, said in the release. “The launch of the TD-300/A, planned for mid-2018, will further optimize Tyvaso therapy for patients and, we believe, reduce the rate of therapy discontinuation associated with the current nebulizer.”

Disclosure: Benkowitz is an employee of United Therapeutics.